Abstract
BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P
Original language | English |
---|---|
Pages (from-to) | 653-661 |
Number of pages | 9 |
Journal | Liver International |
Volume | 37 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 1 2017 |
Keywords
- cirrhosis
- elderly
- genotype 1
- hepatitis C
- simeprevir
- sofosbuvir